ArticleBMC gastroenterology2025
A novel scoring system to identify patients at low risk for hepatocellular carcinoma five years after DAA-Induced sustained virological response: a retrospective cohort study.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTreating chronic hepatitis C virus infection with direct-acting antivirals (DAAs) results in a sustained virological response (SVR) in most cases, but hepatocellular carcinoma (HCC) can occur in some patients after achieving SVR. Thus, this study comprehensively assessed the risk factors associated with the development of HCC during long-term follow-up in patients who achieved SVR. Furthermore, we aimed to identify a group of patients without prior HCC treatment who are at extremely low risk for HCC long after achieving SVR.
methodsThis retrospective cohort study included patients who achieved SVR after DAA therapy, and predictors contributing to the incidence of HCC were determined via Cox regression analysis. Specifically, we evaluated the factors contributing to the incidence of HCC among patients without previous HCC treatment later than 5 years after achieving SVR, and these were used to construct a predictive scoring system for HCC.
resultsOverall, 267 cases of HCC were observed during follow-up. Male sex, older age, previous HCC treatment before starting DAA therapy, excessive alcohol use, diabetes mellitus, elevated γ-GTP, low albumin, and low platelet count were independent predictors of HCC. Since previous HCC treatment strongly influenced the incidence of HCC after SVR, we further analyzed the risk factors for HCC among patients without previous HCC treatment. In that cohort, parameters at 5 years after achieving SVR that contributed to the incidence of HCC later than 5 years after SVR were an age of ≥ 70 years, diabetes mellitus (DM), and fibrosis-4 index(Fib-4) of ≥ 2.67. These three factors were used to create a scoring system, with scores of 0 to 3 predicting a 0.8%, 2.7%, 11.9%, and 28.8%, respectively, cumulative incidence rate of HCC later than 5 years after SVR.
conclusionsUsing long-term follow-up data, we investigated the risk factors for HCC among patients who achieved SVR after DAA therapy. Previous HCC treatment strongly predicted HCC after SVR. Although this was a retrospective cohort study, among patients without previous HCC treatment, those younger than 70 years, without DM and with a Fib-4 index of < 2.67 had a very low risk of developing HCC later than 5 years after SVR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.